Podcasts about Liver disease

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the programHear Me: Patient Perspectives on PBC

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.Moderator: Aleksander Krag Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal All EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Topic: Liver DiseaseEmail the show any time women@mpbonline.org. Hosted on Acast. See acast.com/privacy for more information.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we look at three new pieces of research with implications for general practice.Firstly, can exercise prevent the recurrence of colorectal cancer? Short answer, yes. But how much exercise did you need to do, and what on earth is a MET? Secondly, what are the concerns around low-dose amitriptyline use for IBS from patients and GPs? How can we aid the discussion? Finally, can SLGT2 inhibitors improve liver disease? Is this the new treatment for our patients with MASLD (the condition formerly known as NAFLD? ReferencesNEJM Exercise and CRCMETs WikipediaBJGP IBS & amitriptyline prescribingBMJ SGLT2i & MASLDNB Blog MASLD: The rebrand you never heard ofwww.nbmedical.com/podcast

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prevalence, Risk Factors, and Prognosis for Fontan-Associated Liver Disease: A Systematic Review and Exploratory Meta-Analysis.

Niall McKay talks to Harriet Medeley about her diagnosis of Primary Sclerosing Cholangitis (PSC) and how it inspired her to write Outpatient, an award-winning comedy play which opened in London this month. They discuss how her diagnosis, her life as an artist and mother and turning a life changing disease into art and comedy.

Your liver plays a critical role in your overall health, but signs of trouble can be easy to miss. In this episode, Nurse Doza uncovers the early warning signals of liver dysfunction, from chronic fatigue to weight gain, and explains how your diet, sleep, and stress levels impact liver health. Learn practical steps to support your liver naturally and optimize your well-being. 5 KEY TAKEAWAYS Persistent fatigue is often a sign of liver dysfunction, as the liver regulates energy metabolism. Poor sleep quality, including sleep apnea, is linked to an increased risk of liver disease. Gut health and liver function are closely connected—irregular bowel movements may indicate liver issues. Cognitive decline and brain fog can be early indicators of non-alcoholic fatty liver disease (NAFLD). Weight gain and metabolic imbalances are often tied to liver health and insulin resistance. FEATURED PRODUCT Liver Boost – Packed with essential nutrients to support optimal liver function, Liver Boost promotes detoxification, enhances bile flow, and helps combat oxidative stress. Give your liver the support it needs to function at its best. TIMESTAMPS 00:00 START 03:15 The first sign: Chronic fatigue and liver dysfunction 10:30 How stress and the adrenal glands impact liver health 15:45 The second sign: Poor sleep and its link to liver disease 21:00 The third sign: Gut health and irregular bowel movements 27:10 How your liver processes toxins and the role of bile RESOURCES MENTIONED "How Fatigue and Liver Disease Are Connected" – https://pmc.ncbi.nlm.nih.gov/articles/PMC6676553/ "The Link Between Liver Disease and Sleep Apnea" – https://aapmd.org/sleep-disorders/the-link-between-liver-disease-and-sleep-apnea "Gut Microbiome, IBS, and Liver Disease" – https://pmc.ncbi.nlm.nih.gov/articles/PMC8727221/ "NAFLD and Cognitive Decline" – https://www.neurology.org/doi/10.1212/wnl.0000000000200853 "Weight Gain and Liver Health" – https://pmc.ncbi.nlm.nih.gov/articles/PMC6591731/

TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice. Intended for hepatologists, gastroenterologists, and other clinicians managing liver disease, Liver Lineup will unpack the latest research, debate emerging controversies, and spotlight developments that could shape — or sharpen — day-to-day practice, all with unfiltered perspective and clarity. Brown is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University Reau is a professor of internal medicine, the Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and the section chief of Hepatology at Rush University Medical Center. In the inaugural episode, Brown and Reau introduce the mission behind Liver Lineup and share why they created the podcast. Driven by a shared commitment to education, clinical excellence, and elevating the conversation around liver disease, the hosts describe their hope to offer practicing clinicians a clear, concise, and engaging way to keep up with the latest news and innovations in hepatology. They aim to highlight data that's not only new, but meaningful — spotlighting developments that can improve patient care today and shape best practices tomorrow. Together, the Brown and Reau set the stage for what's to come: expert commentary on major liver meetings including Digestive Disease Week, European Association for the Study of the Liver Congress, The Liver Meeting from the American Association for the Study of Liver Diseases, and the American College of Gastroenterology Annual Meeting; coverage of key topics like MASLD, liver cancer, viral hepatitis, and transplant; and conversations with colleagues across the hepatology spectrum. From debates over practice-changing data to discussions on care pathways and diagnostics, Liver Lineup aims to keep clinicians informed, engaged, and ready to translate insight into impact. Looking ahead, Brown and Reau preview upcoming episodes covering major hepatology updates from Digestive Disease Week 2025 and European Association for the Study of the Liver Congress 2025 — with more to follow throughout the year.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. With results published in The New England Journal of Medicine, hosts are joined by first author Arun J. Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, to discuss key takeaways from part 1 of the ESSENCE trial, semaglutide's impact on liver outcomes and weight loss, and what the data could mean for the future of MASH treatment. ESSENCE Once-weekly semaglutide 2.4 mg significantly improved liver outcomes in patients with metabolic dysfunction–associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, according to findings from the ESSENCE trial. In part 1 of the ongoing, double-blind, placebo-controlled trial, 800 patients were evaluated at 72 weeks for two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and fibrosis improvement without worsening steatohepatitis. Spanning 253 sites in 37 countries, the full trial enrolled 1197 biopsy-confirmed patients between May 2021 and April 2023. At the interim analysis, semaglutide achieved both primary endpoints. Resolution of steatohepatitis without fibrosis worsening occurred in 62.9% of patients receiving semaglutide compared with 34.3% in the placebo group (difference, 28.7%; 95% CI, 21.1–36.2; P

Avec Émile Demers, pharmacien en gastro-entérologie, Geneviève Lahaie-Reilly et Omar El Bissany, nutritionnistes en gastro-entérologie pédiatrique, nous allons:rappeler les bases sur les maladies inflammatoires de l'intestin (MII), soit la maladie de Crohn et la colite ulcéreuse;expliquer les aspects nutritionnels à considérer dans les MII et aborder certains mythes et réalités sur la nutrition;résumer les principaux médicaments couramment utilisés en maladie de Crohn et en colite ulcéreuse.Références:Gordon H. et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment, Journal of Crohn's and Colitis, Volume 18, Issue 10, October 2024.Mack et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019 M. Ruemmele, G. Veres, K.L. Kolho, A. Griffiths, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, Journal of Crohn's and Colitis, Volume 8, Issue 10, October 2014Canisius Fantodji, Marie-Claude Rousseau, Belinda Nicolau, Sreenath Madathil, Andrea Benedetti, Prévost Jantchou. (2024). « Early life exposures and risk of inflammatory bowel disease: A nested case-control study in Quebec, Canada », Digestive and Liver Disease. Crohn's and Colitis Foundation. Standardized Assessment Tools for Pediatric IBD patients. Pediatric Crohn's Disease Activity Index (PCDAI) et Pediatric Ulcerative Colitis Activity Index (PUCAI). Novembre 2017 Critch J, et al. NASPGHAN IBD Committee. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):298-305. Dépliant HSJ: Immunisation et maladie inflammatoire de l'intestin Captation et montage: Philippe Lacroix, spécialiste en audiovisuelIdée originale, réalisation et animation: Émilie Roy-St-PierreConseillères en communication: Katrine Louis-Seize et Pascale ChatagnierLogo: Équipe des communications et du graphisme du CHU Sainte-JustineMusique: Samuel Ross  Collègues, ami(e)s et famille, merci pour votre précieux soutien. © mgparkilo 2025Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

Send us a textWhat happens when “just one glass” turns into a deadly diagnosis?In this raw and riveting episode of Feel Lit Alcohol Free, Ruby Williams and Susan Larkin sit down with Karla Adkins, co-founder of Zero Proof Life and author of She Came Tumbling Down. Karla was a young professional when she was diagnosed with cirrhosis of the liver at just 36—a wake-up call that nearly came too late!Why Karla wrote her riveting book: "I can't be silent anymore. I have to share my story. I want people to know what can happen, the truth of this dangerous game that a lot of people are playing."We dive deep into:✅ The toxic culture of pandemic drinking and “mommy wine” humor✅ Why liver disease is rising rapidly in women ages 25–34✅ What it really takes to heal—physically, emotionally, and spiritually✅ How Karla went from silent shame to powerful sobriety advocateThis conversation is urgent, inspiring, and unforgettable. Let's get into it.Read Karla's compelling story And She Came Tumbling Down : Breaking the Bonds of Alcohol and Creating a Life of Freedom Connect with Karla: Karlaadkins.com  @thezeroprooflife @karlakadkinsListeners have said that our podcast has helped them get alcohol free! So we created Feel Lit 21, a way for you to press your reset button and take a 21 day break from alcohol. Every day you will receive emails with videos, journal prompts, and the inspiration you need to embrace 21 days without alcohol that feels lit! Leave a review on Apple Podcasts, and ask us any questions you have about breaking free from wine or living an alcohol-free lifestyle. Websites:Susan Larkin Coaching https://www.susanlarkincoaching.com/ Ruby Williams at Freedom Renegade Coaching https://www.freedomrenegadecoaching.com/Follow Susan: @drinklesswithsusanFollow Ruby: @rubywilliamscoachingIt is strongly recommended that you seek professional advice regarding your health before attempting to take a break from alcohol. The creators, hosts, and producers of the The Feel Lit Alcohol Free podcast are not healthcare practitioners and therefore do not give medical, or psychological advice nor do they intend for the podcast, any resource or communication on behalf of the podcast or otherwise to be a substitute for such.

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

This episode of VHHA's Patients Come First podcast features Dr. Juan Pablo Arab, a transplant hepatologist and director of alcohol science with the Stravitz-Sanyal Institute for Liver Disease at VCU Health. This conversation covers liver health, insights gleaned from recent research into U.S. liver disease prevalence, the impact of early screening and targeted intervention, and more. Send questions, comments, feedback, or guest suggestions to pcfpodcast@vhha.com or contact on X (Twitter) or Instagram using the #PatientsComeFirst hashtag.

For National Donate Life Month, Health Matters revisits the conversation between our host, Angelique Serrano, and NewYork-Presbyterian and Columbia transplant hepatologist Dr. Alyson Fox. They talk about the differences between living donation and deceased donation, walk through the steps of preparation and recovery for organ donation and transplant, and the importance of this lifesaving gift.___Alyson Fox, MD, is medical director of the adult transplant program at NewYork-Presbyterian and Columbia. Dr. Fox's clinical practice is focused on the management of patients with a variety of liver diseases including viral hepatitis, alcoholic and non-alcoholic fatty liver diseases, inherited and autoimmune liver diseases and liver cancers. As a transplant hepatologist, she has advanced training in the management of the complications of end stage liver disease and caring for patients both pre- and post-liver transplantation. When she is not caring for patients, she is active as a course director and educator at the Columbia University Vagelos College of Physicians and Surgeons.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

In this EASL DeepDive held on 30 October 2024, Henning Grønbæk, Cyrielle Caussy, Mazen Noureddin and Frank Tacke provide an understanding of the role of glucagon and glucagon-receptors in physiology and in MASH patients. Additionally, they review key clinical trials and evaluate the integration of GLP-1 receptor agonists into current EASL-EASD-EASO clinical guidelines for practical patient management.Learning objectives:Understand the role of glucagon and glucagon-receptor in normal physiology and disease.Understand the rationale of a combined dual GLP-1/GCG RA and its potential benefit compared to a GLP-1RA alone and thus gain insights into the mechanisms through which GLP-1 receptor agonists and GLP-1/GCG might affect liver pathology and metabolic regulation.Discuss and review key clinical trials and ongoing development programs.Evaluate how GLP-1RA can be integrated into current EASL-EASD-EASO CPGs, with a focus on practical applications and patient management strategies, giving potential guidance for future applications.This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.Click here to see all EASL Video Podcasts on Apple Podcasts.

A study published in JAMA Internal Medicine found that statin use in patients with chronic liver disease was associated with a lower risk of liver cancer and hepatic decompensation, suggesting potential protective effects beyond lipid management. Surveys by the Annenberg Public Policy Center revealed widespread misinformation about the risks of consuming raw milk, highlighting the need for public education on the importance of pasteurization. New research links red meat allergy (alpha-gal syndrome) to bites from deer ticks and western black-legged ticks, expanding the geographic risk area and emphasizing the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the program Hear Me: Patient Perspectives on PBC

Mándanos un mensaje¿Alguna vez has sentido que sigues todas las reglas pero tu cuerpo no responde como esperabas? La respuesta podría estar en tus biomarcadores, esas pequeñas señales químicas que revelan la verdad sobre tu salud mucho antes que cualquier síntoma visible.Organizaciones de saludAmerican Diabetes Association (ADA): https://diabetes.org/American Heart Association (AHA): https://www.heart.org/World Health Organization (WHO): https://www.who.int/National Institutes of Health (NIH): https://www.nih.gov/Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/Endocrine Society: https://www.endocrine.org/American College of Rheumatology: https://www.rheumatology.org/American Association for the Study of Liver Diseases: https://www.aasld.org/Estudios científicos específicosHemoglobina A1C: American Diabetes Association. (2021). Glycemic Targets: Standards of Medical Care in Diabetes. Diabetes Care, 44(Supplement 1): S73-S84.Ferritina y rendimiento: Sim, M., et al. (2019). Iron considerations for the athlete: a narrative review. European Journal of Applied Physiology, 119(7): 1463-1478.Miocinas: Pedersen, B. K. (2019). Physical activity and muscle-brain crosstalk. Nature Reviews Endocrinology, 15(7): 383-392.Perfil lipídico y riesgo cardiovascular: Grundy, S. M., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 73(24): e285-e350.Vitamina D: Holick, M. F., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 96(7): 1911-1930.Enzimas hepáticas: Kwo, P. Y., et al. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American Journal of Gastroenterology, 112(1): 18-35.Ácido úrico y enfermedad cardiovascular: Borghi, C., et al. (2020). Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology, 145(1): 1-10.Variabilidad de frecuencia cardíaca: Shaffer, F., & Ginsberg, J. P. (2017). An Overview of Heart Rate Variability Metrics and Norms. Frontiers in Public Health, 5: 258.Support the showInstagram: andieillanesPágina web: andieillanes.com.mx

Supported by Gilead Sciences Europe Ltd who provided funding for this content and is intended for healthcare professionals. Gilead Sciences Europe Ltd was not involved in the creation of this content. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Gilead Sciences Europe Ltd or EMJ. Note that not all treatments discussed in this episode may have received market approval. Please refer to your local marketing authorisation and prescribing practices for guidance. The speakers received honoraria. Tune into this episode hosted by Hannah Moir, which discusses what PBC is, and key takeaways from the AASLD conference.

Dr. Centor discusses metabolic dysfunction-associated steatotic liver disease with Dr. Michelle Lai.

What can serum bile acid (BA) levels tell us about cholestatic liver diseases? Credit available for this activity expires: 3/13/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002302?ecd=bdc_podcast_libsyn_mscpedu

Podcast 277 – The Unfiltered Truth About Liver Disease – Beth Lehman – Liver Life Walk at Brook Run Park   Beth Lehman's battle with alcoholism and liver cancer nearly cost her life, but a transplant saved her. Now she's on a mission to raise awareness with the Liver Life Walk Atlanta on April 12th at Brook Run Park. This walk, not a run, ensuring everyone can participate. Beth shares the urgent need for organ donors, and explains how most other countries automatically enroll donors. In the US, it is an opt-in program, and the number of donors is falling. Dunwoody, let's show up and make a difference! liverlifewalk.org/atlanta

This recording features audio versions of March 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Safety and Effectiveness of Early Primary Stent Placement for Hepatic Artery Stenosis in Liver Transplant Recipients ReadThe LAVA Study: A Prospective, Multicenter, Single-Arm Study of a Liquid Embolic System for Treatment of Peripheral Arterial Hemorrhage ReadVenous Stents Placed for Postthrombotic Syndrome: The Role of Inflow Disease on Patency ReadProstatic Artery Embolization: Mid- to Long-Term Outcomes in 1,075 Patients ReadArtificial Intelligence-Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases ReadA Decade Long Analysis of Healthcare Disparities and Uterine Artery Embolization: An Exploration of Social Determinants of Health ReadAlso make sure to check out the issue's special content dedicated to the SIR 50th Anniversary.JVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Brian Tangsombatvisit, University of California San Francisco School of MedicineMatthew Kim, University of California San Francisco School of MedicineCrystal Chin, Touro College of Osteopathic MedicineDave Enriquez, University of California Riverside School of MedicineDaniel Roh, Loma Linda University School of MedicineLauren Lee, Washington State University Elson S. Floyd College of MedicineSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

The Piedmont Transplant Institute in Atlanta performs about 135 liver transplants each year. It's the highest-volume liver transplant center of any nonacademic, community hospital in the United States and is among the top 10% in the nation of all transplant centers.Piedmont's success was achieved primarily because of the collaboration between various interdisciplinary departments—especially IR and hepatology—and an extensive network of referrals.In the audio version of "Transplant teamwork: A community hospital builds successful liver transplant program" (Fall 2019 IR Quarterly), author Melanie Padgett Powers describes a successful Atlanta-based liver transplant program based on a strong collaboration between interventional radiology, hepatology and others.Related resources:Read the original articlePiedmont Transplant Institute websiteSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Dr. Pol Boudes, CMO of Rectify Pharmaceutical, highlights the importance of membrane proteins, specifically the role transporters play in how cells interact with their environment. Rectify is working on developing positive functional modulators (PFM) to address diseases related to dysfunctional transporters the first being primary sclerosing cholangitis, a rare liver disease with no current treatment options. The PFM can potentially restore the normal function of transporters involved in bile composition and secretion, which are key mechanisms in PSC.   Pol explains, "So you have different types of membrane proteins, but what we're working with are called transporters, so they're proteins that are based on the membrane but channel components out and in the cells. So basically, it's a way for the cell to interact with its environment, and you have multiple types of transporter proteins. We're specifically working or started to work with one group of family of proteins that are called the ABC transporters. They're a very important function, and they can either be disrupted because there is a mutation in the protein, so it's a genetic disease, or they are potentially disrupted because there is just a functional deficit of this transporter. The protein is normal, but it's not functioning properly. So it's a functional deficit of what we call the wildtype protein." "So with the PFMs, what we're doing is to use small molecules that you can administer orally, and they bind to the transporter, and by doing so, they can modify the three-dimensional structure of the transporter and consequently the way this protein behaves within the cellular environment. So we correct the function of the transporter by changing the size, if you want, of the shape of the transporter. So we started to focus on this type of proteins and you have many potential diseases due to transporter deficit."  "We're focusing on one disease, liver disease. That's our lead PFM for a disease called primary sclerosing cholangitis, which is a disease of the liver. This very severe liver disease is also a disease that has no treatment available, which is a little bit frustrating because the progression of this disease leads to liver cirrhosis. And the only thing you can do at this stage is liver transplantation. As you might know, liver transplantation is problematic because it's a very complex process, it's also very expensive, and unfortunately, there is a shortage of transplants. So we're trying to address this problem." #RectifyPharma #PrimarySclerosingCholangitis #PSC #RareDisease #LiverDiseases #BileProduction #Transporters rectifypharma.com Download the transcript here

Dr. Pol Boudes, CMO of Rectify Pharmaceutical, highlights the importance of membrane proteins, specifically the role transporters play in how cells interact with their environment. Rectify is working on developing positive functional modulators (PFM) to address diseases related to dysfunctional transporters the first being primary sclerosing cholangitis, a rare liver disease with no current treatment options. The PFM can potentially restore the normal function of transporters involved in bile composition and secretion, which are key mechanisms in PSC.   Pol explains, "So you have different types of membrane proteins, but what we're working with are called transporters, so they're proteins that are based on the membrane but channel components out and in the cells. So basically, it's a way for the cell to interact with its environment, and you have multiple types of transporter proteins. We're specifically working or started to work with one group of family of proteins that are called the ABC transporters. They're a very important function, and they can either be disrupted because there is a mutation in the protein, so it's a genetic disease, or they are potentially disrupted because there is just a functional deficit of this transporter. The protein is normal, but it's not functioning properly. So it's a functional deficit of what we call the wildtype protein." "So with the PFMs, what we're doing is to use small molecules that you can administer orally, and they bind to the transporter, and by doing so, they can modify the three-dimensional structure of the transporter and consequently the way this protein behaves within the cellular environment. So we correct the function of the transporter by changing the size, if you want, of the shape of the transporter. So we started to focus on this type of proteins and you have many potential diseases due to transporter deficit."  "We're focusing on one disease, liver disease. That's our lead PFM for a disease called primary sclerosing cholangitis, which is a disease of the liver. This very severe liver disease is also a disease that has no treatment available, which is a little bit frustrating because the progression of this disease leads to liver cirrhosis. And the only thing you can do at this stage is liver transplantation. As you might know, liver transplantation is problematic because it's a very complex process, it's also very expensive, and unfortunately, there is a shortage of transplants. So we're trying to address this problem." #RectifyPharma #PrimarySclerosingCholangitis #PSC #RareDisease #LiverDiseases #BileProduction #Transporters rectifypharma.com Listen to the podcast here

The beginning of February is my opportunity to again speak with Ellen Bayens of theceliacscene.com about studies and articles she has brought to our attention over the past month.  Ellen and I spoke about the findings of Dr. Diana Mager and her team at the University of Alberta regarding food insecurity in families with a celiac child or children. This is something I covered in a recent podcast with Dr. Mager and something that will help shape the response of Celiac Canada to this issue. Food Insecurity for Celiac Children | A Canadian Celiac Podcast  Cost of Gluten-Free Diet Contributing to Food Insecurity Ellen was able to give us a firsthand introduction to a link between Liver Disease and Celiac Disease that was looked at in a recent study. Celiac Disease Linked to Chronic Liver Disease We also talked about the new recipe phenomenon called egg bites or breakfast cups, which can easily be made gluten free. Ellen has given us the recipe from a trusted gluten free bakery near her. As well, we noted that M&M Food Markets has added a new gluten free dinner entrée to their extensive list of gluten free food. Recipe Alert! Breakfast Egg Cups by Wild Poppy Bistro & Bakery New to M&M Food Market Introduces Thai Chicken Peanut Curry   Ellen mentioned Celiac Canada's webpage regarding information for healthcare professionals in managing patients with celiac disease, which many people have found helpful in dealing with their doctors. www.celiac.ca/healthcare-professionals/management/ Sue's Websites and Social Media – Podcast https://acanadianceliacpodcast.libsyn.com Podcast Blog – https://www.acanadianceliacblog.com Email – acdnceliacpodcast@gmail.com Celiac Kid Stuff – https://www.celiackidstuff.com Baking Website – https://www.suesglutenfreebaking.com Instagram - @suesgfbaking YouTube - https://www.youtube.com/playlist?list=PLUVGfpD4eJwwSc_YjkGagza06yYe3ApzL Email – sue@suesglutenfreebaking.com

Earlier this year iECURE reported that an infant with the rare and deadly liver disease OTC deficiency had a complete response to its experimental gene editing therapy. It is believed to be the time that an infant was treated with an in vivo, liver-directed gene editor. The treatment restored ammonia levels in the child's blood to normal and the child is off of ammonia scavenger medicines and is eating a normal diet. We spoke to Joe Truitt, CEO of iECURE, about the company's experimental therapy for OTC, how it works, and its approach to in vivo gene editors.

In this episode, host Courtney Allison discusses the latest studies on the health risks associated with alcohol use with Dr. Robert Brown, chief of Gastroenterology and Hepatology at NewYork-Presbyterian and Weill Cornell Medicine. They discuss how alcohol affects various organs, including your liver, heart, and brain, as well as its link to several cancers. Dr. Brown discusses the cultural perception of alcohol, the current guidelines around safe drinking limits, and how binge drinking harms the body. 

Episode 31  In this episode, we will be discussing hepatic failure.  Topics include:Functions of the liver as a basis for understanding the diseaseFindings in cirrhotic liver diseaseDiagnostic findings in cirrhotic liver diseaseTreatment of liver diseaseHead over to my website to subscribe to my email group!  I send out sample CCRN & PCCN Questions and will be starting a newsletter in 2025!  Click here to join:  https://kayhoppepresents.com/To get my full CCRN Review Online Course, click here:   https://kay-hoppe-presents.teachable.com/p/ccrn-reviewTo get my full PCCN Review Online Course, CLICK HERE:  https://kay-hoppe-presents.teachable.com/p/pccn-review

Joey Mattingly is an associate professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S.S. Tu, S. Kottilil, and T.J. Mattingly II. Leveraging Old Hepatitis C Therapies. N Engl J Med 2025;392:1-4.

Text and Be HeardIs alcohol truly the festive elixir we often believe it to be, or does it mask a darker reality during the Christmas season? This episode dives into the multifaceted role of alcohol during the holidays, examining how it can be both a source of joy and a potential peril. We explore the cultural tendencies that lead many to overindulge, risking their health and well-being in the process. From the sobering statistics linking alcohol to chronic diseases and accidents to its use as a crutch for loneliness and depression, we shine a light on the serious consequences that often accompany holiday cheer.28 Million Alcoholics in USA,  11% of people 12+400 Million Alcoholics in the World   15+Europe has 15% of their people labeled as AlcoholicsAlcohol increases Chronic Diseases, Mental Health, Liver Disease, Accidents, Injuries and Violence, both Domestic Violence and Homicides.As we navigate this complex relationship, we share insights from the Recovery Freedom Circle, a beacon for those seeking to reclaim their lives from addiction. With over 27 years of Recovery, we discuss the profound benefits of a life without alcohol, including increased energy and enhanced self-worth. We challenge listeners to reconsider the way they celebrate, advocating for a focus on health, family, and the true spirit of Christmas. By prioritizing well-being and embracing a lifestyle of sobriety, you can enrich your life and strengthen your connections with loved ones, turning the festive season into a celebration of genuine joy and spirituality.Support the showRecovery is Beautiful. Go Live Your Best Life!!Facebook Group - Recovery Freedom Circle | FacebookYour EQ is Your IQYouTube - Life Is Wonderful Hugo VRecovery Freedom CircleThe System That Understands Recovery, Builds Character and Helps People Have Better Relationships.A Life Changing Solution, Saves You Time, 18 weekswww.lifeiswonderful.love Instagram - Lifeiswonderful.LoveTikTok - Lifeiswonderful.LovePinterest - Lifeiswonderful.LoveTwitter - LifeWonderLoveLinkedIn - Hugo Vrsalovic Life Is Wonderful.Love

Losing a baby in the early stages of pregnancy can be an extremely painful experience. Having to explain to your employer why you can't come to work only adds to the difficulty. In the UK, there's currently no entitlement to time off for miscarriage within the first six months of pregnancy. The Women and Equalities Select Committee is hearing evidence on extending the right to bereavement leave to cover losses up to 24 weeks. Sarah Owen MP, Chair of the Committee and someone who has experienced baby loss, joined Nuala McGovern to discuss. When the Stammer Came to Stay is award-winning author Maggie O'Farrell's third children's book. Based on her experience of living with a stammer, it celebrates differences and explores children's resilience in facing new challenges. She talks to Anita Rani about the book and how her stammer has shaped her life. Why are more young women dying from alcohol-related liver disease than ever before? BBC journalist Hazel Martin, diagnosed with the condition in her early 30s, has been investigating how her social drinking habits put her life at risk. Hazel joined Nuala along with Professor Debbie Shawcross, Consultant Hepatologist at King's College Hospital, to explore the growing crisis and its causes. After writing her Spinal Column for The Times since 2010 —beginning just two weeks after breaking her neck and back in a riding accident—Melanie Reid has decided it's time to stop. She joined Nuala to discuss why she's stepping away, her reflections on the journey, and her plans for the future. Song-writing partnership Abigail Barlow and Emily Bear are making history by becoming the youngest and first female songwriting duo to compose for a Disney feature film in Moana 2. The Grammy Award-winning pair joined Nula to discuss their musical partnership. Kim Cypher, a saxophonist, composer, and vocalist, is a regular on the London and UK jazz circuit. She recently launched her third album, Catching Moments, and joined Anita in the Woman's Hour studio and performed live.Presenter: Anita Rani Producer: Dianne McGregor

Gain expert insights into best practices in diagnosing progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Credit available for this activity expires: 11/25/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001956?ecd=bdc_podcast_libsyn_mscpedu

Chantay Harrison-Crawford, a resilient 35 year-old woman, navigates life with Sickle Cell Anemia, Liver Disease, and various medical complications stemming from Sickle Cell Disease. Despite facing immense personal challenges, in 2019, she courageously founded Tilted Crown I Inc., a testament to her strength and determination. In 2023, Chantay confronted rock-bottom moments as she grappled with her own and her daughter's separate suicide attempts, triggered by toxic relationships within her family and circle of friends. Through adversity, she found a renewed purpose after a divine intervention during her second suicide attempt, leading her to dedicate herself to self-transformation and following a higher calling. As a mother, professional, wife, and entrepreneur, Chantay now channels her energy into fostering mental and emotional well-being. She initiated the "Royal Bible Study" program, aiming to empower women towards self-love and care, building on her commitment to serving others. Concurrently, she extended her compassion by offering shelter to two homeless individuals in Illinois. Chantay's past initiatives like "Wisdom Wednesday," documenting stories of Sickle Cell Warriors, and providing community support reflect her altruistic nature. Notably, she has also launched programs such as "Melanated Warrior" and "PMS - Pray and Manifesting Ish," emphasizing natural remedies for Sickle Cell Anemia and hosting relatable discussions through a weekly podcast. Embarking on a new chapter, she is set to release her first book under She Rises Studios, expected between November 2024 and January 2025, marking a significant milestone in her journey of resilience and empowerment. Her social media presence on Instagram as @Catica.33, TikTok as @dearcatica.333, and podcasts on IHeartRadio, Apple Podcasts, and Spotify under "Dear Catica.33" showcase her commitment to sharing experiences and insights.

Patients are amazed at the things Dr. Prather picks up on during an initial examination.  But he says this is possible when you know how to interpret the language of your body's symptoms in a holistic way.  In this episode, we talk about:—Why men (and doctors) are "the worst" when it comes to ignoring symptoms that need to be checked out.—The levator scapulae test Dr. Prather uses to identify stress in a patient.  And how patients with severe Depression and Anxiety will often not have relief until the levator scapulae is released. —How a Cardiac Ear Crease on the ear lobe is an indicator of cardiovascular disease.  And how a blemish on the ear can indicate a problem in a specific area of the body.—The link between thickened toe nails and cardiovascular disease.  And how swelling in the ankles (edema) can indicate Kidney Disease or Heart Disease based on upon whether it's in both ankles or just one ankle.—How the loss of hair on a man's legs is an indication of cardiovascular disease.  And how the loss of eyebrows, usually in women, can be an indication of gallbladder disease.—What bags under the eyes and dark circles around the eyes indicate about Kidney Disease and Liver Disease.  And how Plantar Fasciitis can even be a sign of Kidney Disease.—Why Dr. Prather says the Emergency Room should be called for a Gallbladder emergency surgery when a patient says their stool has a white color.  And what a healthy bowel movement should look like.—What urine color, frequency, and the force of your urination reveal about the health of your Kidneys.—How Dr. Prather has "never" had a Headache case where he wasn't able to find the underlying cause.  And how the different types of Headache symptoms help point to the source of the problem.—Why pain should never be ignored because there is always a reason for the pain.  And why Structure-Function Care should be the primary care for a patient.http://www.TheVoiceOfHealthRadio.com

David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, the focus of other MASH drugs.  David explains, "Sagimet was founded back in 2007 as a private company with a group of medicinal chemists that had a particular target in mind, and this particular target was called fatty acid synthase, or FASN. FASN is a rather ubiquitous enzyme throughout the body that functions as a regulating enzyme in many organs. When FASN becomes overactive or overexpressed, it sort of throws things out of balance and, in particular, certain cardiometabolic diseases, such as MASH and in the liver. So, this group of chemists, in order to resolve this overactivity, developed a portfolio of FASN inhibitors, led by our lead program denifanstat, that seek to target the underlying cause of MASH and, therefore, really work to limit the activity of FASN, try to normalize it essentially is what we do." "For us and this particular molecule, it offers a differentiated approach to treating the disease for us and this particular molecule. Our molecule, denifanstat, is the only FASN inhibitor. It's the only fat inhibitor in development for MASH, making it rather unique. All the rest of the molecules or fat burners, fat oxidizers, and fat mobilizers include GLPs, FGF, and THR-beta. They all function by trying to burn fat peripherally and in the liver to a degree. They rely on that fat-burning mechanism to translate into reductions, inflammation, and fibrosis, which is important to treating MASH, but they've had varying degrees of success. Our molecule targets each pathway independently: fat, inflammation, and fibrosis, and has had a rather pronounced treatment effect as a result."  #SagimetBiosciences #MASH #FattyLiverDisease #FASN #FASNInhibitor #Fibrosis #Obesity #NASH #GLP1Agonists sagimet.com Download the transcript here

David Happel is President and CEO of Sagimet Biosciences, a company developing drugs to treat metabolic diseases by targeting the underlying cause of fat accumulation in the liver. The drug denifanstat limits the activity of fatty acid synthase (FASN), an enzyme that regulates fat accumulation. This approach is a fat inhibitor, not a fat burner, the focus of other MASH drugs.  David explains, "Sagimet was founded back in 2007 as a private company with a group of medicinal chemists that had a particular target in mind, and this particular target was called fatty acid synthase, or FASN. FASN is a rather ubiquitous enzyme throughout the body that functions as a regulating enzyme in many organs. When FASN becomes overactive or overexpressed, it sort of throws things out of balance and, in particular, certain cardiometabolic diseases, such as MASH and in the liver. So, this group of chemists, in order to resolve this overactivity, developed a portfolio of FASN inhibitors, led by our lead program denifanstat, that seek to target the underlying cause of MASH and, therefore, really work to limit the activity of FASN, try to normalize it essentially is what we do." "For us and this particular molecule, it offers a differentiated approach to treating the disease for us and this particular molecule. Our molecule, denifanstat, is the only FASN inhibitor. It's the only fat inhibitor in development for MASH, making it rather unique. All the rest of the molecules or fat burners, fat oxidizers, and fat mobilizers include GLPs, FGF, and THR-beta. They all function by trying to burn fat peripherally and in the liver to a degree. They rely on that fat-burning mechanism to translate into reductions, inflammation, and fibrosis, which is important to treating MASH, but they've had varying degrees of success. Our molecule targets each pathway independently: fat, inflammation, and fibrosis, and has had a rather pronounced treatment effect as a result."  #SagimetBiosciences #MASH #FattyLiverDisease #FASN #FASNInhibitor #Fibrosis #Obesity #NASH #GLP1Agonists sagimet.com Listen to the podcast here

In the last five years, doctors have seen a growing number of patients who need liver transplants because of alcohol use, and sometimes people aren't even aware they're drinking too much. Then, how an indie movie could help Colorado's film industry rebound. Also, stories from a Colorado centenarian about the obstacles he's overcome in his life -- and the rules he lives by. And Colorado Wonders about election security. 

In this podcast, Contributing Editor Berkeley Limketkai, MD, PhD, interviews Dr. Trevor Tabone on the article “Intestinal Failure-Associated Liver Disease: Current Challenges in Screening, Diagnosis and Parenteral Nutrition Considerations” published in the August 2024 issue of NCP. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US October 2024

Interview with Fasiha Kanwal, MD, MSHS, author of GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Hosted by Eve Rittenberg, MD, and Grace Yuan Zhang, MD Related Content: GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Get ready for another informative episode that raises awareness and empowers people to share their stories about Hepatitis C, featuring Sarah Laurel and Dr. Daniel Moore. Hello, this is Vincent A. Lanci and welcome back to the number 1 podcast show for mental health advocates and champions, "A Mental Health Break." YOU ARE NOT ALONE.Our Guests will discuss more about:-How their health experiences can help make a difference and build a community.-Raising awareness about Hepatitis C, how it is transmitted, and the fact that this disease affects over 4 million people in the US. -How can Hepatitis C be treatedDaniel Moore, MD, MBA, FACEP, physician and co-owner of Thoroughbred Emergency Physicians. He is recognized as a national leader in the field of emergency medicine in quality, safety, and communicable diseases. Sarah Laurel: After overcoming substance use disorder, Sarah was inspired to create resources for women facing similar challenges. What started as a grassroots effort has since evolved into a program offering housing, street outreach, and nationwide training. Drawing from her own experiences, Sarah remains deeply connected to those still on their recovery journey, using her story to inspire and support others. If you enjoy today's show, please subscribe for all episodes and leave a review to help others join our conversations. Have a question for the host or guest? Are you looking to become a show partner? Email Danica at PodcastsByLanci@gmail.com to get connected.CRISIS LINE: DIAL 988

Did you know that your liver performs over 500 vital functions in your body? Join us for an eye-opening episode of the Ancient Health Podcast as host Courtney Bursich interviews Kristin Kirkpatrick, a renowned Registered Dietitian and liver health expert. Kristin, author of "Skinny Liver" and "Regenerative Health," shares her invaluable insights on the crucial role of the liver in metabolic health and overall well-being. In this episode, we delve deep into the world of liver health, exploring its impact on everything from energy levels to cognitive function. Discover: The hidden signs of liver dysfunction you might be overlooking Why your waistline could be a window into your liver's health The surprising link between your liver and unexplained mood swings How fasting might be the key to regenerating your liver cells The truth about detox diets and what really helps your liver Why spending time in nature could be as important for your liver as what's on your plate The sleep-liver connection you never knew existed Tune in to arm yourself with practical, actionable strategies to support your liver's health. Whether you're looking to boost your energy, clear brain fog, or simply optimize your overall health, this episode is packed with game-changing information you can't afford to miss. By the end, you'll walk away with a roadmap to revitalize your liver and transform your health from the inside out. #liverhealth #metabolichealth #nutrition #wellness #detox #functionalmedicine #healthyliving Want more of The Ancient Health Podcast? Subscribe to the YouTube channel. Follow Dr. Josh Axe Instagram Follow Dr. Chris Motley Instagram Follow Courtney Bursich Instagram Follow Kristin Kirkpatrick Instagram ------  Links:  Kristinkirkpatrick.com ------  Ads: *Subscribe to The Dr. Josh Axe Show wherever you listen to your podcasts to take your mental, spiritual, and physical health to the next level! Grab your free Healing Leaky Gut and Essential Oils 101 course at www.joshaxe.com/podcast for a limited time!

OMS4 Rebecca Shaneck guides us through a rapid review of the high yield liver diseases you will see in board exams. If you find the liver confusing, start here to develop a foundation!

In May we did a podcast on KidneyPal (the integration of palliative care in renal disease), which made us think, hmmm… one organ right next door is the liver. Maybe we should do a podcast on LiverPal? (or should we call it HepatoPal?) On today's podcast, we do that by inviting four palliative care leaders who are integrating palliative care into the care of those with liver disease: Kirsten Engel, Sarah Gillespie-Heyman, Brittany Waterman, and Amy Johnson. It's a jampacked 50 minutes, filled with pearls on taking care of patients with liver disease.  We cover: How each of their LiverPal teams are structured Why and how LiverPal differ from general palliative care or other palliative care specialty areas (KidneyPal, PalliPulm, etc) How to prognosticate in liver disease and how they communicate this with patients How to think about expectations of transplants and limitations of it How to manage complications and symptoms ranging from ascites, hepatic encephalopathy, pain, itching, cramps, and depression Also, if you want to take an ever deeper dive, check out our 2022 podcast on End Stage Liver Disease with Jen Lai, Ricky Shinall, Nneka Ufere, and Arpan Patel

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Julia Wattacheril is a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. In this episode, Julia delves deep into the complex world of liver health, beginning with a foundational overview of liver physiology. She provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. She provides a primer on the four major stages of liver disease, discussing risk and emphasizing the importance of early diagnosis. Julia highlights the role of liver disease in increasing the risk of cancer and cardiovascular disease and covers in detail the various strategies for diagnosing, treating, and preventing the progression of liver disease. We discuss: Julia's training, the importance of liver health, and the challenges and innovations of hepatology [3:15]; The complex and crucial functionality of the liver, its four most essential functions, and more [8:45]; Liver injuries: historical and evolving understanding of causal factors, and the progression to liver diseases and cancer [13:15]; How the liver metabolizes nutrients and what happens in the presence of excess calories or alcohol [24:45]; Methods of diagnosing liver disease and how insights guide treatment and management strategies [33:30]; The poisonous nature of ethanol to the liver [40:30]; Varied responses to alcohol, damaging effects of alcohol beyond the liver, and the process of advising patients on their alcohol consumption [47:15]; Understanding liver enzymes AST and ALT—interpreting levels, lifestyle factors that affect them, and diagnostic approaches [58:30]; Interpreting liver function tests for fatty liver disease, and the challenges of diagnosing liver pathologies, particularly in children versus adults [1:13:15]; Comprehensive liver health assessments via imaging and various diagnostic tools to prevent overlooking potential liver pathologies [1:18:45]; Potential impact of recreational drugs, statins, and other medications on liver function test results [1:26:45]; Shifting nomenclature from NAFLD to MASLD to reflect accuracy in the underlying pathophysiology and understanding of liver diseases [1:30:30]; Pathophysiology of MASLD, the need for proactive screening, and the significance of liver fat percentage as an indicator of metabolic health [1:36:30]; The importance of screening for rare conditions alongside common metabolic diseases associated with fatty liver accumulation [1:42:45]; Practical strategies for managing MAFLD [1:45:30]; The impact of fructose consumption on liver health and the challenges of disentangling its effects from other factors like obesity and insulin resistance [1:52:45]; The potential of GLP-1 agonists for the treatment of MASLD [1:57:45]; How the four stages of liver disease have evolved [2:00:30]; Increased cancer and heart disease risk associated with early-stage MAFLD [2:05:15]; Emerging drugs and therapies for addressing fat accumulation and fibrosis related to MAFLD [2:12:15]; Peter's major takeaways [2:18:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube